Search Results
Your search for Matthew Stenger matches 7791 pages
Showing 1 - 50Glofitamab Plus Polatuzumab Vedotin in Relapsed or Refractory Large B-Cell Lymphoma
In a phase Ib/II trial reported in the Journal of Clinical Oncology, Hutchings et al found that the combination of glofitamab and polatuzumab vedotin was associated with high activity in patients with relapsed or refractory large B-cell lymphoma, including high-grade B-cell lymphoma. Study Details...
Ruxolitinib in Steroid-Refractory Acute GVHD: Final Analysis From REACH2
As reported in the Journal of Clinical Oncology by Mohty et al, the final analysis of the phase III REACH2 trial indicates that ruxolitinib provided efficacy advantages over the best available therapy (BAT) in patients with steroid-refractory acute graft-vs-host disease (GVHD) after allogeneic...
Pembrolizumab Plus Chemotherapy Without Radiotherapy in Unresectable Locally Advanced NSCLC With High PD-L1 Expression
In a Japanese phase II trial (Evolution) reported in The Lancet Oncology, Hata et al found that pembrolizumab plus platinum-based chemotherapy without radiotherapy was active in unresectable locally advanced non–small cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50%. Study...
Neoadjuvant Dual ICI Blockade vs Perioperative FLOT in dMMR/MSI-H Gastroesophageal Adenocarcinoma
In an individual-patient pooled analysis reported in the Journal of Clinical Oncology, Raimondi et al found that neoadjuvant treatment with dual CTLA-4/PD-(L)1 immune checkpoint inhibitors (ICIs) was associated with higher pathologic response rates vs perioperative FLOT (fluorouracil, leucovorin,...
Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma: 9-Year Follow-Up of CheckMate 238
As reported at the latest ESMO Congress and in The New England Journal of Medicine by Ascierto et al, the 9-year follow-up of the phase III CheckMate 238 trial showed a continued recurrence-free survival benefit with adjuvant nivolumab vs ipilimumab in patients with resected stage IIIB–C or IV...
Disitamab Vedotin Plus Toripalimab vs Chemotherapy in HER2-Expressing Advanced Urothelial Cancer
In a Chinese phase III trial (RC48-C016) reported at the recent ESMO Congress and in The New England Journal of Medicine, Sheng et al found that the combination of the HER2-directed antibody-drug conjugate disitamab vedotin and the PD-1 inhibitor toripalimab-tpzi improved progression-free survival...
Sacituzumab Tirumotecan in EGFR-Mutated Advanced NSCLC
In a Chinese phase III trial (OptiTROP-Lung-04) reported at the recent ESMO Congress and published in The New England Journal of Medicine, Fang et al found that monotherapy with sacituzumab tirumotecan (sac-TMT)—an antibody-drug conjugate targeting trophoblast cell–surface antigen 2—was associated...
Unresectable Stage III NSCLC: Addition of Simultaneous Durvalumab to Chemoradiotherapy
As reported in the Journal of Clinical Oncology by Bradley et al, the phase III PACIFIC-2 trial showed no significant progression-free survival benefit with the simultaneous addition of durvalumab to concurrent platinum-based chemoradiotherapy (cCRT) in patients with unresectable stage III...
Risk Factors for Valvular Heart Disease Among Childhood Cancer Survivors
In a study reported in JAMA Oncology, Glele et al identified potential risk factors for valvular heart disease (VHD) in a European cohort of long-term childhood cancer survivors. Study Details The nested case-control study used data from the PanCareSurFup (PanCare Childhood and Adolescent Cancer...
Cervical Cancer: SLNB Alone vs Lymphadenectomy
In a Chinese phase III trial (PHENIX) reported in The New England Journal of Medicine, Tu et al found that sentinel lymph node biopsy (SLNB) alone was noninferior in disease-free survival vs lymphadenectomy in women with early-stage cervical cancer and was associated with fewer surgical...
Clinical Usefulness of Linking Whole-Genome Data to Mortality Statistics in UK Patients With Breast Cancer
In a retrospective analysis reported in The Lancet Oncology, Black et al examined whether linking of comprehensive whole-genome sequencing (WGS) to mortality data could add prognostic value to standard clinical data and provide a rationale for use of targeted therapies. Study Details In the...
State of the Hematology and Medical Oncologist Workforce in the United States
In a study reported in JCO Oncology Practice, Kirkwood et al identified recent changes in and characteristics of the hematologist/medical oncologist (oncologist) workforce in the United States, with the data revealing gaps in coverage according to age and other patient demographics. Study Details ...
First-Line PD-1/PD-L1 Inhibitors vs BRAF Plus MEK Inhibitors in BRAF V600E–Mutated Metastatic NSCLC
In a retrospective cohort study (FRONT-BRAF) reported in The Lancet Oncology, Di Federico et al found that first-line PD-1 or PD-L1 inhibitors with or without platinum-based chemotherapy were associated with improved overall survival compared with BRAF and MEK inhibitors in patients with metastatic ...
Risk of Colorectal Subsequent Malignant Neoplasms in Childhood Cancer Survivors
In a Childhood Cancer Survivor Study analysis reported in the Journal of Clinical Oncology, Owens et al identified the risks of colorectal subsequent malignant neoplasms (SMNs) associated with colorectal-specific radiotherapy (RT) doses and chemotherapy doses among 5-year survivors of childhood...
Survival With Dual CTLA-4 and PD-L1/PD-1 Blockade in Advanced NSCLC
In a systematic review and reconstructed individual-patient meta-analysis reported in The Lancet Oncology, Di Federico et al found that dual CTLA-4 and PD-L1 or PD-1 blockade did not result in improved long-term survival overall vs single PD-L1 or PD-1 blockade in patients with advanced non–small...
Chemotherapy-Free Regimen vs Standard Immunochemotherapy in Mantle Cell Lymphoma in Older Patients
In a phase II/III study (ENRICH) reported in The Lancet, Lewis et al found that the chemotherapy-free combination of ibrutinib plus rituximab prolonged progression-free survival vs standard immunochemotherapy in patients aged 60 years or older with previously untreated mantle cell lymphoma. Study...
Combination Therapies for Diffuse Large B-Cell Lymphoma: 5-Year Outcomes of the POLARIX Trial
As reported in the Journal of Clinical Oncology by Morschhauser et al, the 5-year findings of the POLARIX trial showed a continued benefit with polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin, and prednisone (Pola-R-CHP) vs rituximab, cyclophosphamide, doxorubicin, vincristine,...
First-Line Ribociclib at 400 vs 600 mg in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer
In a phase II trial (AMALEE) reported in JAMA Oncology, Cardoso et al found that a first-line ribociclib dose of 400 mg was not noninferior to a dose of 600 mg in patients with newly diagnosed hormone receptor–positive, HER2-negative advanced breast cancer. Study Details In the open-label...
Ziftomenib in Relapsed or Refractory NPM1-Mutant AML
As reported in the Journal of Clinical Oncology by Wang et al, a phase I/II trial (KOMET-001) has shown activity of the oral menin inhibitor ziftomenib in patients with relapsed or refractory NPM1-mutant acute myeloid leukemia (AML). Study Details In the phase II portion of the trial, 92 patients...
Systemic Anticancer Therapy at End of Life and Health-Care Use Among Older Patients
In a linked Surveillance, Epidemiology, and End Results (SEER)–Medicare analysis reported in the Journal of Clinical Oncology, Canavan et al found that receipt of systemic anticancer therapy (SACT) at the end of life (EOL) was associated with higher rates of EOL emergency department (ED) use,...
Inotuzumab Ozogamicin Followed by Blinatumomab in Older Patients With Newly Diagnosed B-Cell ALL
As reported in the Journal of Clinical Oncology by Wieduwilt et al, findings in a cohort of the phase II Alliance study A041703 indicate that the chemotherapy-free regimen of inotuzumab ozogamicin followed by blinatumomab was highly active in patients aged ≥ 60 years with newly diagnosed B-cell...
Genetic Modification of the AJCC Classification for Papillary Thyroid Cancer
In an international, multicenter retrospective cohort study reported in The Lancet Oncology, Xing et al found that incorporating the genetic status of BRAF and TERT genes into the American Joint Committee on Cancer (AJCC) staging system for papillary thyroid cancer resulted in a modification of...
Dexamethasone-Sparing Regimen for Frail Patients With Newly Diagnosed Multiple Myeloma
In a French phase III trial (IFM2017-03) reported in The Lancet Oncology, Manier et al found that a dexamethasone-sparing regimen of daratumumab plus lenalidomide improved progression-free survival vs lenalidomide plus dexamethasone in patients with frailty and newly diagnosed multiple myeloma....
Association of Survival With Treatment Recommendation and Receipt in Older Patients With Early-Stage Cervical Cancer
In a retrospective cohort study reported in JAMA Network Open, Suk et al identified the association of survival with receipt of recommended treatment and nonreceipt of nonrecommended treatment among patients aged ≥ 65 years with newly diagnosed early-stage cervical cancer. Study Details The study...
Patient-Reported Outcomes and Overall Survival in Cancer
In a systematic review and meta-analysis reported in JAMA Oncology, Huang et al found that patient-reported outcomes (PROs) provide prognostic information for overall survival in patients with cancer. Study Details A systematic review of studies published between January 2000 and June 2024 was...
Pembrolizumab Plus Platinum-Based Chemotherapy in Advanced Penile Cancer
In a Brazilian phase II trial (HERCULES; LACOG 0218) reported in JAMA Oncology, Maluf et al found that pembrolizumab plus platinum-based chemotherapy showed activity in patients with advanced penile squamous cell carcinoma. The investigators explained, “Advanced penile squamous cell carcinoma is...
Sunvozertinib in Platinum-Pretreated NSCLC With EGFR Exon 20 Insertion Mutations
In a phase II trial (WU-KONG1B) reported in the Journal of Clinical Oncology, Yang et al found that the EGFR tyrosine kinase inhibitor sunvozertinib was active at both dose levels tested in patients with platinum-pretreated non–small cell lung cancer (NSCLC) with EGFR exon 20 insertion mutations....
Variation in PSA Levels in Annual Testing Among Individuals Without a Prostate Cancer Diagnosis
In a study reported in JAMA Oncology, Pickersgill et al found that individuals without prostate cancer undergoing annual prostate-specific antigen (PSA) testing often exhibited a PSA level below biopsy threshold in the year following an elevated test result. Study Details The study involved data on ...
Impact of HER2-Receptor Status in mCRC Treated With Chemotherapy Plus Bevacizumab or Anti-EGFR Agents
In an analysis reported in the Journal of Clinical Oncology, Germani et al identified the impact of HER2 status in patients with metastatic colorectal cancer (mCRC) receiving chemotherapy plus either bevacizumab or anti-EGFR agents. Study Details The study involved data from 1,604 patients with...
Association of TERT Expression With Outcomes in Meningioma
In an analysis reported in The Lancet Oncology by Gui et al in the International Consortium on Meningiomas, TERT expression in meningiomas was found to be associated with poorer progression-free survival. Study Details The multi-institutional cohort study involved retrospectively collected data...
Impact of Novel Donor Search Strategy on Outcomes for Potential HCT Recipients
In a study (BMT CTN 1702) reported in the Journal of Clinical Oncology, Lee et al found little difference in 2-year survival outcomes between patients considered “very likely” vs “very unlikely” to find an HLA-matched unrelated donor (MUD) for allogeneic hematopoietic cell transplantation as...
Modified FOLFIRINOX vs Gemcitabine/Nab-Paclitaxel in Metastatic Pancreatic Cancer
In a phase II trial (PASS-01) reported in the Journal of Clinical Oncology, Knox et al found similar progression-free survival with modified leucovorin, fluorouracil, irinotecan, oxaliplatin (mFOLFIRINOX) vs gemcitabine/nab-paclitaxel in patients with previously untreated metastatic pancreatic...
Addition of Xevinapant to Platinum-Based Chemoradiotherapy in Unresected Locally Advanced Squamous Cell Carcinoma of the Head and Neck
In a phase III trial (TrilynX) reported in the Journal of Clinical Oncology, Bourhis et al found that the addition of xevinapant (an inhibitor of apoptosis proteins inhibitor) to platinum-based chemoradiotherapy did not improve event-free survival in patients with unresected locally advanced...
Localized PI3K-Altered Colorectal Cancer: Does Low-Dose Aspirin Reduce the Risk of Recurrence?
In a Scandinavian trial (ALASCCA) reported in The New England Journal of Medicine, Martling et al found that low-dose aspirin reduced the risk of disease recurrence vs placebo in patients with PI3K-altered localized colorectal cancer. Study Details In the double-blind trial, patients with stage I...
Neoadjuvant FOLFIRINOX vs Gemcitabine-Based Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma
In a Dutch phase III trial (PREOPANC-2) reported in The Lancet Oncology, Janssen et al found no difference in overall survival between patients receiving neoadjuvant FOLFIRINOX vs neoadjuvant gemcitabine-based chemoradiotherapy for resectable or borderline resectable pancreatic ductal...
Medical Imaging and Risk of Pediatric and Adolescent Hematologic Cancer
In a study reported in The New England Journal of Medicine, Smith-Bindman et al found that medical imaging among children was associated with a significantly increased risk of pediatric and adolescent hematologic cancer. The study involved data from a retrospective cohort of 3,724,623 children born ...
Amivantamab Plus Lazertinib vs Osimertinib in EGFR-Mutated NSCLC: Overall Survival in MARIPOSA
As reported in The New England Journal of Medicine by Yang et al, the final overall survival analysis in the phase III MARIPOSA trial has shown significant benefit with amivantamab plus lazertinib vs osimertinib in patients with previously untreated EGFR-mutated advanced non–small cell lung cancer...
Use of Pazopanib in Advanced Extrapancreatic Neuroendocrine Tumors
In a phase II trial (Alliance A021202) reported in the Journal of Clinical Oncology, Bergsland et al found that pazopanib prolonged progression-free survival vs placebo in patients with advanced extrapancreatic neuroendocrine tumors (epNETs). However, as stated by the investigators, pazopanib will...
Metastasis-Directed Radiotherapy for Oligometastatic Clear Cell Renal Cell Carcinoma
In a single-center phase II trial reported in The Lancet Oncology, Tang et al found that metastasis-directed radiotherapy without systemic therapy was associated with good outcomes in patients with oligometastatic clear cell renal cell carcinoma. Study Details In the trial, 121 patients...
Proton Craniospinal Irradiation for Leptomeningeal Metastasis in Lung or Breast Cancer
In an interim analysis of a phase II trial reported in JAMA Oncology, Yang et al found that proton craniospinal irradiation (pCSI) improved central nervous system (CNS) progression-free survival vs photon involved-field radiotherapy (IFRT) in patients who have breast cancer or non–small cell lung...
Overall Survival After Hormonal Therapy vs Hysterectomy in Early Endometrial Cancer
In a U.S. cohort study reported in JAMA Oncology, Suzuki et al assessed long-term survival among premenopausal women with clinical stage I endometrioid endometrial cancer treated with fertility-preserving hormonal therapy vs hysterectomy. Study Details The study focused on National Cancer Database...
Adjuvant Chemoradiotherapy vs Radiotherapy for High-Risk Endometrial Cancer: 10-Year PORTEC-3 Outcomes
In a preplanned 10-year analysis from the phase III PORTEC-3 trial reported in The Lancet Oncology, Post et al found that adjuvant chemoradiotherapy was associated with improved overall survival and recurrence-free survival vs radiotherapy in women with high-risk endometrial cancer. Study Details...
Chronic Toxicity Rates With De-escalated vs Standard Adjuvant Radiotherapy in HPV-Associated Oropharyngeal Squamous Cell Carcinoma
In a U.S. two-center phase III trial (MC1675) reported in The Lancet Oncology, Ma et al found that de-escalated adjuvant radiotherapy was associated with a reduced cumulative, chronic grade ≥ 3 toxicity rate at 3 to 24 months after radiotherapy compared with standard adjuvant treatment in patients...
Addition of Metastasis-Directed SBRT to Standard Therapy in Oligometastatic Castration-Resistant Prostate Cancer
In a Canadian phase II trial (GROUQ-PCS 9) reported in The Lancet Oncology, Niazi et al found that the addition of metastasis-directed stereotactic body radiotherapy (SBRT) to standard systemic therapy improved radiographic progression-free survival in patients with oligometastatic...
Benmelstobart Plus Anlotinib vs Sunitinib as First-Line Treatment of Advanced Renal Cell Carcinoma
In an interim analysis of a Chinese phase III trial (ETER100) reported in The Lancet Oncology, Zhou et al found that the combination of the PD-L1 inhibitor benmelstobart and anlotinib improved progression-free survival vs sunitinib in the first-line treatment of advanced clear cell renal cell...
Noncancer-Related Mortality in RCTs With Targeted Screening
In a meta-analysis reported in JAMA Network Open, Lei et al found a small nonsignificant increase in off-target mortality from noncancer causes or cancers that were not the target of screening in randomized controlled trials (RCTs) with screened and unscreened populations. As stated by the...
Tislelizumab-Based Triplet Therapy for Conversion of Unresectable to Resectable Locally Advanced Biliary Tract Cancer
In a Chinese phase II trial (ZSAB-TransGOLP) reported in The Lancet Oncology, Shi et al found promising results with tislelizumab plus lenvatinib and GEMOX (gemcitabine plus oxaliplatin) chemotherapy (GOLP) in converting unresectable locally advanced biliary tract cancer to resectable disease....
Addition of Neoadjuvant TAR-200 to Cetrelimab in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
In an interim analysis of a phase II trial (SunRISe-4) reported in The Lancet Oncology, Necchi et al found that the addition of neoadjuvant TAR-200—a targeted releasing system that provides sustained delivery of gemcitabine within the bladder—to the PD-1 inhibitor cetrelimab resulted in a higher...
All-Trans Retinoic Acid and Arsenic Trioxide in High-Risk Acute Promyelocytic Leukemia
As reported in the Journal of Clinical Oncology by Platzbecker et al, the European intergroup phase III APOLLO trial showed that an all-trans retinoic acid (ATRA) plus arsenic trioxide (ATO; ATRA-ATO)–based regimen was associated with improved event-free survival vs a standard ATRA plus...
GLP-1 RAs and Cancer Risk in Adults With Overweight/Obesity
In a retrospective study reported in JAMA Oncology, Dai et al found that use of GLP-1 receptor agonists (GLP-1 RAs) for weight loss in adults with overweight/obesity was associated with an overall reduction in risk of cancer. As stated by the investigators, “…GLP-1 RAs… are widely prescribed for...
